BR112012025844A2 - uso de nanofibras snag - Google Patents

uso de nanofibras snag

Info

Publication number
BR112012025844A2
BR112012025844A2 BR112012025844A BR112012025844A BR112012025844A2 BR 112012025844 A2 BR112012025844 A2 BR 112012025844A2 BR 112012025844 A BR112012025844 A BR 112012025844A BR 112012025844 A BR112012025844 A BR 112012025844A BR 112012025844 A2 BR112012025844 A2 BR 112012025844A2
Authority
BR
Brazil
Prior art keywords
compositions
snag nanofibers
bacterial
bacterial infection
treating
Prior art date
Application number
BR112012025844A
Other languages
English (en)
Portuguese (pt)
Inventor
N Vournakis John
Finkielsztein Sergio
Original Assignee
Marine Polymer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Tech Inc filed Critical Marine Polymer Tech Inc
Publication of BR112012025844A2 publication Critical patent/BR112012025844A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112012025844A 2010-04-15 2011-04-15 uso de nanofibras snag BR112012025844A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32465710P 2010-04-15 2010-04-15
PCT/US2011/032709 WO2011130646A1 (en) 2010-04-15 2011-04-15 Anti-bacterial applications of poly -n-acetylglucosamine nanofibers

Publications (1)

Publication Number Publication Date
BR112012025844A2 true BR112012025844A2 (pt) 2017-07-18

Family

ID=44799052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012025844A BR112012025844A2 (pt) 2010-04-15 2011-04-15 uso de nanofibras snag

Country Status (12)

Country Link
US (5) US8858964B2 (https=)
EP (1) EP2563371A4 (https=)
JP (3) JP2013523898A (https=)
KR (1) KR101883797B1 (https=)
CN (2) CN103108638B (https=)
AU (1) AU2011239466B2 (https=)
BR (1) BR112012025844A2 (https=)
CA (1) CA2796068C (https=)
IL (1) IL222375A (https=)
MX (1) MX342912B (https=)
NZ (2) NZ703163A (https=)
WO (1) WO2011130646A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008219065B2 (en) 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
BR112012025844A2 (pt) 2010-04-15 2017-07-18 Marine Polymer Tech Inc uso de nanofibras snag
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
US20140322722A1 (en) * 2011-09-30 2014-10-30 The Research Institute At Nationwide Children's Hospital Compositions and methods for detection of defensins in a patient sample
RU2014151567A (ru) * 2012-05-22 2016-07-10 Новартис Аг Конъюгат менингококка серогруппы х
US20150237837A1 (en) * 2012-06-18 2015-08-27 Duke University Non-Human Model for Wound Healing
WO2014098865A1 (en) 2012-12-20 2014-06-26 Hill's Pet Nutrition, Inc. Pattern recognition receptor expression as a measure of systemic health
US20150024014A1 (en) 2013-03-14 2015-01-22 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
JP2015048436A (ja) * 2013-09-03 2015-03-16 公立大学法人福井県立大学 植物の耐病性を向上させる、生物由来キチン質含有物、その使用方法、及びその製造方法
EP3034612A1 (en) 2014-12-16 2016-06-22 Greenaltech, S.L. Chitin and chitosan producing methods
US10500222B2 (en) * 2015-10-19 2019-12-10 Wayne State University Compositions and methods relating to treatment of infection
CN107460140B (zh) * 2016-06-02 2020-11-13 浙江科技学院 一种芽孢杆菌hz16中抑制军团菌活性物的制备方法
CN111212569B (zh) * 2017-08-31 2025-01-24 辛格隆股份公司 用于制备细菌素和抗微生物肽的方法和组合物
WO2019217796A1 (en) * 2018-05-11 2019-11-14 Marine Polymer Technologies, Inc. Use of poly-n-acetylglucosamine nanofibers for the treatment of gingival recession
BR102021021376A2 (pt) * 2021-10-25 2023-05-09 União Brasileira De Educação Católica - Ubec Composição, processo de produção da composição e uso da composição de nanofibras que compreende pva, quitosana, antibiótico e peptídeo de defesa do hospedeiro
IT202200004574A1 (it) 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni
KR102846669B1 (ko) * 2022-04-14 2025-08-13 충남대학교산학협력단 miRNA 24가 봉입된 키토산 나노입자를 유효성분으로 포함하는 에드워드시엘라 피스시시다에 대한 어류용 항생 조성물
CN115671368B (zh) * 2022-10-28 2024-03-22 东华大学 一种用于生物膜清除的纳米纤维复合贴片及其制备方法

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1038367A (en) 1963-05-28 1966-08-10 Beecham Group Ltd Penicillin derivatives
US3989535A (en) 1974-02-11 1976-11-02 American Cyanamid Company Solution of poly(N-acetyl-D-glucosamine)
US3988411A (en) 1974-02-11 1976-10-26 American Cyanamid Company Spinning and shaping poly-(N-acetyl-D-glucosamine)
US4068757A (en) 1976-11-03 1978-01-17 American Cyanamid Company Chitin derived powder in sterile surgical element package
US4195175A (en) 1978-01-03 1980-03-25 Johnson Edwin L Process for the manufacture of chitosan
JPS55152705A (en) 1979-05-18 1980-11-28 Mitsubishi Rayon Co Ltd Preparation of water-soluble alkali chitin
JPS56131639A (en) 1980-03-21 1981-10-15 Kureha Chem Ind Co Ltd Protein-chitosan composition
US4378017A (en) 1980-03-21 1983-03-29 Kureha Kagaku Kogyo Kabushiki Kaisha Composite material of de-N-acetylated chitin and fibrous collagen
JPS56133344A (en) 1980-03-21 1981-10-19 Kureha Chem Ind Co Ltd Novel composite material
US4532134A (en) 1981-04-06 1985-07-30 Malette William Graham Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound
US4394373A (en) 1981-04-06 1983-07-19 Malette William Graham Method of achieving hemostasis
US4470397A (en) 1981-11-11 1984-09-11 Lucas Industries Public Limited Company Fuel injection pumping apparatus
US4605623A (en) 1982-11-08 1986-08-12 Malette William Graham Method of altering growth and development and suppressing contamination microorganisms in cell or tissue culture
JPS5998660A (ja) 1982-11-26 1984-06-07 House Food Ind Co Ltd 麺類の乾燥方法
JPS59156770A (ja) 1983-02-25 1984-09-06 Canon Inc インパクト型プリンタ
JPS58220899A (ja) 1983-03-22 1983-12-22 工業技術院長 キチン系抄造体の製造方法
JPS6025003A (ja) 1983-07-20 1985-02-07 Shiro Okamura 光磁気記録装置
US4803168A (en) 1983-09-01 1989-02-07 Damon Biotech, Inc. Microencapsulation with polymers
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPS60208302A (ja) 1984-03-31 1985-10-19 Unitika Ltd キチン成形体の製造方法
JPS60215003A (ja) 1984-04-10 1985-10-28 Unitika Ltd キトサン成形体の製造方法
EP0171254B1 (en) 1984-08-03 1991-06-19 Unitika Ltd. Shaped chitin body
JPH0611810B2 (ja) 1984-08-23 1994-02-16 ユニチカ株式会社 多孔性キチン成形体及びその製造方法
JPS61253065A (ja) 1985-05-02 1986-11-10 片倉チツカリン株式会社 キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法
US4895724A (en) 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
DE3751938T2 (de) 1986-06-06 1997-02-27 Union Carbide Corp Saure dekristallisierung von hochkristallin chitosan oder teilentacetylierten chitin
JPS62288602A (ja) 1986-06-06 1987-12-15 Agency Of Ind Science & Technol キトサン変性物粒子の製造方法
JPH0441422Y2 (https=) 1986-10-17 1992-09-29
JPH0525289Y2 (https=) 1987-01-21 1993-06-25
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4942129A (en) 1987-07-28 1990-07-17 Queen's University At Kingston Multiple membrane microencapsulation
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH0532702Y2 (https=) 1987-10-09 1993-08-20
JP2560363B2 (ja) 1987-12-23 1996-12-04 ライオン株式会社 キチン又はキトサン類の精製法
EP0330106A1 (de) 1988-02-25 1989-08-30 Akzo Nobel N.V. Modifizierte Cellulose für biocompatible Dialysemembranen II und Verfahren zu deren Herstellung
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5008116A (en) 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
DE3903797A1 (de) 1989-02-09 1990-08-16 Hoechst Ag Verfahren zur herstellung von aktivierten chitosanen und deren verwendung bei der herstellung von chitosanderivaten
JPH0657761B2 (ja) 1989-02-27 1994-08-03 富士紡績株式会社 多孔質キトサン成形物の製造法
JPH02240101A (ja) 1989-03-14 1990-09-25 Lion Corp 硫酸化キトサン誘導体及びその製造方法
EP0390481B1 (en) 1989-03-23 1996-02-28 Sanyo Chemical Industries Ltd. Surgical adhesive sheet
IT1229167B (it) 1989-04-10 1991-07-22 Texcontor Ets Complessi del ferro o di altri metalli con derivati solfonati del chitosano
US5071977A (en) 1989-05-10 1991-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Plaque inhibiting oligosaccharide
AU5885690A (en) 1989-07-11 1991-01-17 Union Carbide Chemicals And Plastics Company Inc. Emulsions comprising aminopolysaccharides
US5116747A (en) 1989-08-11 1992-05-26 University Of Waterloo Immobilization of biologically active material in capsules prepared from a water-soluble polymer and chitosan acetate
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
DE69015775T2 (de) 1989-10-31 1995-05-11 Howmedica Chitinderivate enthaltende Zusammensetzungen zur Verhütung der Adhäsion.
JPH064531B2 (ja) 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
US5463022A (en) 1990-08-17 1995-10-31 Drug Delivery System Institute, Ltd. N-acetylcarboxymethylchitosan derivatives and process for preparation thereof
ES2103003T3 (es) 1990-08-30 1997-08-16 Warner Lambert Co Articulos formados de una fusion de almidon termoplastica.
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
JPH04126701U (ja) 1991-05-13 1992-11-18 株式会社日立製作所 潤滑機能を有する下部軸受
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
JPH0691819B2 (ja) 1991-05-27 1994-11-16 工業技術院長 デアセチラーゼの製造方法
JP3046099B2 (ja) 1991-06-19 2000-05-29 ユニチカ株式会社 キチン又はキトサンの綿状物
CA2072395A1 (en) 1991-07-01 1993-01-02 John T. Hunt Bicyclic endothelin analogues
JPH0525289A (ja) 1991-07-19 1993-02-02 Unitika Ltd キチン成形体の製造法
JPH0532702A (ja) 1991-08-01 1993-02-09 Unitika Ltd 細胞接着性キチン
JPH0551465A (ja) 1991-08-23 1993-03-02 Unitika Ltd 球状キチンの製造方法
US5229123A (en) 1991-10-09 1993-07-20 Hoffmann-La Roche Inc. Antifungal agents
US5219749A (en) 1991-10-09 1993-06-15 Institute For Molecular Biology & Biotechnology/Forth Process for isolating and preparing purified chitin deacetylase
EP0610441A4 (en) 1991-10-29 1996-01-10 Clover Cons Ltd CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
HUT67665A (en) 1991-11-05 1995-04-28 Smithkline Beckman Corp Indane and indene deriv.s as endothelin receptor antagonists, pharmaceutical compn.s contg. them and process for prepg. them
IL100096A (en) 1991-11-20 1996-03-31 Univ Ramot Method for entrapment of active materials in chitosan
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
DE4200080A1 (de) 1992-01-03 1993-09-30 Reinmueller Johannes Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung
JPH05235905A (ja) 1992-02-21 1993-09-10 Toshiba Corp Ｃｒｃ演算装置
JPH076126A (ja) 1992-02-26 1995-01-10 Nec Corp プロセッサ間バス伝送方式
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
JPH05271094A (ja) 1992-03-26 1993-10-19 Fuji Photo Film Co Ltd カルボキシメチル化キチン誘導体を用いる癌転移抑制剤
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
WO1994003483A1 (en) 1992-07-30 1994-02-17 Chiron Corporation Endothelin receptor-binding compounds
US5871985A (en) 1992-09-28 1999-02-16 Brown University Research Foundation Particulate non cross-linked chitosan core matrices for encapsulated cells
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5447505A (en) 1993-08-04 1995-09-05 Merocel Corporation Wound treatment method
JPH07102458A (ja) 1993-09-30 1995-04-18 Unitika Ltd キチンウェブ状物
US6743783B1 (en) * 1993-12-01 2004-06-01 Marine Polymer Technologies, Inc. Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine
US5846952A (en) 1993-12-01 1998-12-08 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5635493A (en) 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US5622834A (en) 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5686115A (en) 1993-12-01 1997-11-11 Marine Polymer Technologies, Inc. Poly-β-1→4-N-acetylucosamine copolymer composition with collagen
US5624679A (en) 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US5858350A (en) 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
WO1996011927A1 (en) 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
TW313568B (https=) 1994-12-20 1997-08-21 Hoffmann La Roche
US5658943A (en) 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
WO1996039122A1 (en) 1995-06-06 1996-12-12 Marine Polymer Technologies, Inc. POLY-β-1→4-N-ACETYLGLUCOSAMINE
FR2736835B1 (fr) 1995-07-17 1997-10-10 Aber Technologies Pansement pour plaies chroniques, notamment escarres, en gel de chitine
US5998468A (en) 1995-08-24 1999-12-07 Warner-Lambert Company Furanone endothelin antagonists
WO1997037987A1 (en) 1996-04-10 1997-10-16 Warner-Lambert Company Ketoacid endothelin antagonists
US5804594A (en) 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
WO1998033781A1 (en) 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
US20030060434A1 (en) 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ZA987019B (en) 1997-08-06 1999-06-04 Focal Inc Hemostatic tissue sealants
DK0897914T3 (da) 1997-08-19 2004-09-27 Hoffmann La Roche Fremgangsmåde til fremstilling af 2,5-disubstituerede pyridiner
US6046179A (en) 1998-04-17 2000-04-04 Murch; Simon Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
CA2234936C (en) 1998-04-17 2004-06-29 Glucogenics Pharmaceuticals Inc. Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
DE19821598A1 (de) 1998-05-14 1999-11-18 Henkel Kgaa Verfahren zum Abbau von Biopolymeren
TW585762B (en) 1999-11-11 2004-05-01 Tanabe Seiyaku Co Pharmaceutical composition for prophylaxis or treatment of inflammatory bowel diseases
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US7371403B2 (en) 2002-06-14 2008-05-13 Providence Health System-Oregon Wound dressing and method for controlling severe, life-threatening bleeding
US8741335B2 (en) 2002-06-14 2014-06-03 Hemcon Medical Technologies, Inc. Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan
JP2003128704A (ja) 2001-10-24 2003-05-08 Matsumoto Shika Univ キチン・キトサンの低分子化方法及び骨伝導物の製造方法
GB0126923D0 (en) 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
MXPA04004572A (es) 2001-11-14 2005-07-05 Ralph Ryback Metodo para el tratamiento de enfermedades autoinmunes.
JP3947391B2 (ja) * 2001-11-28 2007-07-18 独立行政法人 日本原子力研究開発機構 橋かけ構造を有するキチン誘導体及び／又はキトサン誘導体の製造方法
US20090130186A1 (en) * 2002-06-14 2009-05-21 Hemcon Medical Technologies, Inc. Wound dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan and incorporating silver nanoparticles
US7037983B2 (en) 2002-06-14 2006-05-02 Kimberly-Clark Worldwide, Inc. Methods of making functional biodegradable polymers
FR2843125B1 (fr) 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
WO2004024196A1 (en) 2002-09-11 2004-03-25 Johnson & Johnson Medical Limited Wound dressings for the treatment of wound infection
GB2393120A (en) 2002-09-18 2004-03-24 Johnson & Johnson Medical Ltd Compositions for wound treatment
US20070237812A1 (en) 2006-04-11 2007-10-11 Tyco Healthcare Group Multi-layer wound dressings
WO2004060172A1 (en) 2002-12-31 2004-07-22 Marine Polymer Technologies, Inc. Hemostatic compositions and uses therefor
JP5028086B2 (ja) * 2003-02-24 2012-09-19 マリン ポリマー テクノロジーズ，インコーポレーテッド 細胞−ポリマー繊維組成物及びその使用
NZ546204A (en) 2003-09-12 2009-12-24 Marinepolymer Tech Inc Vascular access preservation in haemodialysis patients
CA2538760A1 (en) 2003-09-19 2005-03-31 Otsuka Pharmaceutical Co., Ltd. Human .beta.-defensin secretion promoter
RU2240830C1 (ru) 2003-12-26 2004-11-27 ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов Раневое покрытие и способ его получения
AU2004314731B2 (en) 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
US7704522B2 (en) 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
CA2487564A1 (en) 2004-11-12 2006-05-12 Valorisation Recherche Hscm Folic acid-chitosan-dna nanoparticles
DE102004061406A1 (de) 2004-12-21 2006-07-06 Bayer Innovation Gmbh Infektionsresistente Polyurethanschäume, Verfahren zu ihrer Herstellung und Verwendung in antiseptisch ausgestatteten Wundauflagen
US20070036846A1 (en) * 2005-08-15 2007-02-15 Tsang Wing W M Wound dressing and method of manufacture thereof
CA2628313A1 (en) 2005-11-04 2007-05-31 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
US8277849B2 (en) 2006-01-19 2012-10-02 Solazyme, Inc. Microalgae-derived compositions for improving the health and appearance of skin
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
US20100150960A1 (en) 2006-09-22 2010-06-17 The United States Of America, As Represented By The Secretary,Department Of Health And Human Servi Compositions and methods for chitosan enhanced immune response
WO2008048076A1 (en) 2006-10-20 2008-04-24 Amorepacific Corporation A composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them
KR100882611B1 (ko) 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
BRPI0807065A2 (pt) 2007-01-31 2017-03-21 Allergan Inc biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos
AU2008219065B2 (en) * 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
ES2324192B1 (es) * 2008-01-30 2010-06-17 PUIG BEAUTY & FASHION GROUP, S.L. Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas.
US8436157B2 (en) 2008-03-26 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
AP2011005537A0 (en) 2008-07-18 2011-02-28 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins.
US20100086613A1 (en) 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
BR112012025844A2 (pt) 2010-04-15 2017-07-18 Marine Polymer Tech Inc uso de nanofibras snag
CA2833415A1 (en) 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
WO2012061803A2 (en) 2010-11-06 2012-05-10 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
US20140363673A1 (en) 2011-05-15 2014-12-11 National University Corporation Tottori University Therapeutic agent for inflammatory bowel disease
US20150024014A1 (en) 2013-03-14 2015-01-22 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers

Also Published As

Publication number Publication date
WO2011130646A1 (en) 2011-10-20
US20160235774A1 (en) 2016-08-18
EP2563371A1 (en) 2013-03-06
HK1185278A1 (zh) 2014-02-14
US8858964B2 (en) 2014-10-14
US9198928B2 (en) 2015-12-01
NZ602909A (en) 2015-01-30
AU2011239466A1 (en) 2012-11-01
KR20130069625A (ko) 2013-06-26
IL222375A0 (en) 2012-12-31
US10561677B2 (en) 2020-02-18
CN103108638A (zh) 2013-05-15
US20130129789A1 (en) 2013-05-23
JP2016196466A (ja) 2016-11-24
AU2011239466B2 (en) 2015-01-22
JP2018203766A (ja) 2018-12-27
NZ703163A (en) 2016-06-24
US20150140045A1 (en) 2015-05-21
CA2796068C (en) 2022-07-19
KR101883797B1 (ko) 2018-08-30
US20190247410A1 (en) 2019-08-15
JP6400628B2 (ja) 2018-10-03
MX2012011816A (es) 2013-01-22
US9642871B2 (en) 2017-05-09
US20180099003A1 (en) 2018-04-12
MX342912B (es) 2016-10-19
CA2796068A1 (en) 2011-10-20
JP6761453B2 (ja) 2020-09-23
CN103108638B (zh) 2016-11-09
US10206938B2 (en) 2019-02-19
EP2563371A4 (en) 2013-10-23
JP2013523898A (ja) 2013-06-17
CN107412772A (zh) 2017-12-01
IL222375A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
BR112012025844A2 (pt) uso de nanofibras snag
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BR112012029521A2 (pt) leucocidinas do staphylococcus aureus, composições terapêuticas, e aplicações das mesmas.
BRPI0922220B8 (pt) uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BRPI0810064B8 (pt) compostos contendo nitrogênio tricíclico como agentes antibacterianos, composições farmacêuticas que compreendem os ditos compostos e uso dos mesmos para o tratamento de infecções bacterianas em mamíferos
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
ZA202002093B (en) Antibacterial compounds
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
ES2571998T3 (es) Composiciones y usos médicos de derivados del ajoeno
BR112016016854A2 (pt) Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados
MX2011008043A (es) Derivados de actagardina.
MX2012000136A (es) Composiciones que comprenden finafloxacina y metodos para tratar infecciones oftalmicas, oticas, o nasales.
CU20090216A7 (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
HK1243951A1 (zh) 抗微生物组合和其在治疗微生物感染中的用途
CL2013000331A1 (es) Compuestos derivados de triazina-1,2 diazol condezada o de triazina-1,2,4-triazol condensada; proceso para preparar estos compuestos; composicion farmaceutica; proceso para preparar esta composicion farmaceutica; y su uso para el tratamiento de una infeccion bacteriana tal como una infeccion por la bacteria clostridium.
CL2021003592A1 (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos.
WO2021081110A3 (en) Peptides and use thereof
BRPI0913586A8 (pt) combinação, e, uso de uma combinação.
UY31954A (es) 3-(n-heterociclil)-pirrolidinil-fenil-oxazolidinonas como agentes antibacterianos
UY31953A (es) 3-cianopirrolidinil-fenil-oxazolidinonas como agentes antibacterianos
MX2015008036A (es) Compuestos antibacterianos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements